title: Human T cell lymphotropic virus-associated leukemia/lymphoma.
abstract: OBJECTIVE
  This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options.
  
  
  RESULTS
  New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition.
  
  
  CONCLUSIONS
  Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
authors.affiliation: Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. lratner@im.wustl.edu
authors.forename: Lee
authors.initials: L
authors.lastname: Ratner
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000906:Antibodies / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015480:Deltaretrovirus Antibodies / Q000627:therapeutic use; D015368:Human T-lymphotropic virus 1 / Q000472:pathogenicity*; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000503:physiopathology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000503:physiopathology*; D011379:Prognosis; D033581:Stem Cell Transplantation
chemical_list: D044966:Anti-Retroviral Agents; D000906:Antibodies; D000970:Antineoplastic Agents; D015480:Deltaretrovirus Antibodies